Fig. 6

p38 mitogen-activated protein kinase (MAPK) and NF-kB pathways in R848 stimulated IgG production. Purified (magnetic beads) splenic CD19⁺ B cells from pristane-treated mice (a) and PBS-treated mice (b) were stimulated with R848 alone or with R848 plus p38 MAPK inhibitor SB203580 (SB80) (10 μM) or NF-κB classical pathway inhibitor JSH23 (5 μM) for 10 days. IgG in supernatants was measured with ELISA: *p <0.05; **p <0.01 (paired t test) vs. dimethyl sulfoxide (DMSO)/R848 control